Payment overview · 2025
General Payments
$3,204.90
142 reported records · 24 companies
Healthcare provider profile · identity verified
Anna Milstein, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · LOS ANGELES, CA · NPI 1003914227
Verified facts
What the public records show
CMS Open Payments records show Anna Milstein, M.D. received $3,204.90 in general payments during 2025 across 142 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 11.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brilinta, Creon, Eliquis, Farxiga, Flector, Jardiance, Kerendia, Leqvio, Linzess, Mounjaro, Nexletol, Nurtec Odt, Ozempic, Prolia, Trelegy Ellipta, Verquvo, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 471 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 468 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 909 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 605 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 376 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Nexletol by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Trelegy Ellipta by this doctor in 2024.
IBSA Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Flector as an associated drug or biological on 6755 records involving 4085 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Flector by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 353 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 1409 claims for Entresto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LEQVIO as an associated drug or biological on 126702 records involving 33819 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Leqvio by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 344 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 376 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $369.51 | 11.5% | 20 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $293.69 | 9.2% | 16 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $291.63 | 9.1% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $273.08 | 8.5% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $220.08 | 6.9% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $192.85 | 6.0% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $187.63 | 5.8% | 8 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $181.24 | 5.7% | 7 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $162.71 | 5.1% | 11 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $131.46 | 4.1% | 5 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $129.18 | 4.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $107.96 | 3.4% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $89.56 | 2.8% | 4 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $88.73 | 2.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $77.36 | 2.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $75.11 | 2.3% | 3 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $59.80 | 1.9% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $53.95 | 1.7% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $51.98 | 1.6% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $49.12 | 1.5% | 2 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $42.24 | 1.3% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $35.66 | 1.1% | 1 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $22.90 | 0.7% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $17.47 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,204.90 | 142 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $297.35 | 15 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $291.63 | 12 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $220.08 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $164.52 | 10 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $162.71 | 11 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $150.61 | 6 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $147.27 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $135.82 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $134.68 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $131.82 | 6 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $131.46 | 5 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $129.18 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $129.17 | 6 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $119.50 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $99.34 | 6 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $88.73 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $77.36 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $70.92 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $66.00 | 3 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $59.80 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $53.95 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $51.98 | 2 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $49.12 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.25 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.25 | 2 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $42.24 | 2 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $42.24 | 2 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $42.24 | 2 | 2025 |
Source payment records
|
|||||
| BRILINTA Normalized: brilinta |
Drug | AstraZeneca Pharmaceuticals LP | $40.81 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $35.66 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $32.27 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $22.90 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $17.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRILINTA brilinta |
2025 | Brilinta | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 471 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 376 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 605 | exact normalized | Medicare Part D |
| Flector flector |
2025 | Flector | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 99 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 154 | exact normalized | Medicare Part D |
| LEQVIO leqvio |
2025 | Leqvio | 2024 | 26 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 468 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 353 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 73 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 344 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 60 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 204 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 140 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 65 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
471 | 60 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
468 | 55 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
909 | 104 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
60 | 45 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
605 | 84 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
154 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
376 | 46 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
204 | 31 |
| IBSA Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | Flector open payments reported associated product |
CMS Open Payments — General Payments 6755 supporting records · 4085 recipient NPIs · example record 1211687357 |
Flector · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
353 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
140 | 17 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
1409 | 156 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | LEQVIO open payments reported associated product |
CMS Open Payments — General Payments 126702 supporting records · 33819 recipient NPIs · example record 1200004747 |
Leqvio · 2024 Exact normalized brand match · 1 Part D row |
26 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
344 | 48 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
376 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Entresto | Sacubitril/Valsartan | 1409 | 156 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1018 | 123 |
| Xarelto | Rivaroxaban | 959 | 104 |
| Furosemide | Furosemide | 927 | 105 |
| Synthroid | Levothyroxine Sodium | 909 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 901 | 98 |
| Carvedilol | Carvedilol | 830 | 95 |
| Atorvastatin Calcium | Atorvastatin Calcium | 797 | 102 |
| Vascepa | Icosapent Ethyl | 761 | 96 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 683 | 82 |
| Nebivolol Hcl | Nebivolol Hcl | 671 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 608 | 81 |
| Farxiga | Dapagliflozin Propanediol | 605 | 84 |
| Potassium Chloride | Potassium Chloride | 584 | 58 |
| Pitavastatin Calcium | Pitavastatin Calcium | 582 | 77 |
| Doxazosin Mesylate | Doxazosin Mesylate | 576 | 64 |
| Clonidine Hcl | Clonidine Hcl | 565 | 99 |
| Icosapent Ethyl | Icosapent Ethyl | 515 | 64 |
| Amiodarone Hcl | Amiodarone Hcl | 510 | 56 |
| Spironolactone | Spironolactone | 498 | 63 |
| Ranolazine Er | Ranolazine | 488 | 50 |
| Creon | Lipase/Protease/Amylase | 471 | 60 |
| Linzess | Linaclotide | 468 | 55 |
| Metformin Hcl | Metformin Hcl | 456 | 61 |
| Dapagliflozin | Dapagliflozin Propanediol | 435 | 59 |
| Dexlansoprazole Dr | Dexlansoprazole | 435 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 411 | 53 |
| Liothyronine Sodium | Liothyronine Sodium | 410 | 42 |
| Eliquis | Apixaban | 376 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 363 | 65 |
| Losartan Potassium | Losartan Potassium | 357 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 356 | 42 |
| Mounjaro | Tirzepatide | 353 | 43 |
| Repatha Sureclick | Evolocumab | 350 | 53 |
| Praluent Pen | Alirocumab | 347 | 49 |
| Ozempic | Semaglutide | 344 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 269 | 44 |
| Febuxostat | Febuxostat | 262 | 31 |
| Gabapentin | Gabapentin | 258 | 36 |
| Allopurinol | Allopurinol | 233 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 231 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 224 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 224 | 32 |
| Eszopiclone | Eszopiclone | 219 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 216 | 28 |
| Nitroglycerin | Nitroglycerin | 208 | 42 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 204 | 31 |
| Lidocaine | Lidocaine | 195 | 25 |
| Edarbi | Azilsartan Medoxomil | 194 | 29 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 192 | 27 |
| Ezetimibe | Ezetimibe | 183 | 21 |
| Tramadol Hcl | Tramadol Hcl | 176 | 30 |
| Atenolol | Atenolol | 173 | 24 |
| Memantine Hcl | Memantine Hcl | 171 | 20 |
| Multaq | Dronedarone Hcl | 168 | 19 |
| Omeprazole | Omeprazole | 166 | 29 |
| Kerendia | Finerenone | 154 | 17 |
| Montelukast Sodium | Montelukast Sodium | 150 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 145 | 17 |
| Januvia | Sitagliptin Phosphate | 144 | 17 |
| Simvastatin | Simvastatin | 143 | 16 |
| Verquvo | Vericiguat | 140 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 137 | 20 |
| Irbesartan | Irbesartan | 134 | 15 |
| Lorazepam | Lorazepam | 129 | 19 |
| Clonidine | Clonidine | 128 | 20 |
| Telmisartan | Telmisartan | 122 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 15 |
| Livalo | Pitavastatin Calcium | 116 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 20 |
| Valsartan | Valsartan | 108 | 19 |
| Sertraline Hcl | Sertraline Hcl | 105 | 13 |
| Captopril | Captopril | 102 | 14 |
| Flecainide Acetate | Flecainide Acetate | 99 | suppressed |
| Jardiance | Empagliflozin | 99 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 98 | 15 |
| Dayvigo | Lemborexant | 97 | 15 |
| Meclizine Hcl | Meclizine Hcl | 96 | 18 |
| Pregabalin | Pregabalin | 92 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 88 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 15 |
| Doxepin Hcl | Doxepin Hcl | 85 | 15 |
| Inpefa | Sotagliflozin | 85 | 13 |
| Alprazolam | Alprazolam | 84 | 14 |
| Famotidine | Famotidine | 82 | suppressed |
| Glimepiride | Glimepiride | 81 | 11 |
| Clonazepam | Clonazepam | 78 | suppressed |
| Colchicine | Colchicine | 78 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 77 | suppressed |
| Tradjenta | Linagliptin | 77 | 11 |
| Propafenone Hcl Er | Propafenone Hcl | 76 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 75 | 11 |
| Mirtazapine | Mirtazapine | 74 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 73 | suppressed |
| Chlorthalidone | Chlorthalidone | 71 | 16 |
| Digoxin | Digoxin | 71 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 71 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 70 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 69 | suppressed |
| Dutasteride | Dutasteride | 68 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 67 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 66 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 65 | suppressed |
| Bumetanide | Bumetanide | 62 | suppressed |
| Prolia | Denosumab | 60 | 45 |
| Metformin Er Gastric | Metformin Hcl | 58 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 58 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 56 | suppressed |
| Nateglinide | Nateglinide | 56 | suppressed |
| Rybelsus | Semaglutide | 55 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 54 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 54 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 53 | suppressed |
| Finasteride | Finasteride | 52 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 52 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 52 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 51 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 50 | suppressed |
| Belsomra | Suvorexant | 48 | suppressed |
| Metolazone | Metolazone | 48 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 47 | suppressed |
| Repatha Pushtronex | Evolocumab | 47 | suppressed |
| Temazepam | Temazepam | 47 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 46 | suppressed |
| Azithromycin | Azithromycin | 44 | 37 |
| Lokelma | Sodium Zirconium Cyclosilicate | 44 | 12 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 43 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 42 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 41 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 40 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 40 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Eplerenone | Eplerenone | 39 | suppressed |
| Brilinta | Ticagrelor | 38 | suppressed |
| Celecoxib | Celecoxib | 38 | suppressed |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | 11 |
| Nexletol | Bempedoic Acid | 37 | suppressed |
| Corlanor | Ivabradine Hcl | 36 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Gemtesa | Vibegron | 34 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Torsemide | Torsemide | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | suppressed |
| Zaleplon | Zaleplon | 30 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Procto-Med Hc | Hydrocortisone | 27 | suppressed |
| Leqvio | Inclisiran Sodium | 26 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Sotalol | Sotalol Hcl | 26 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Nystatin | Nystatin | 25 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Benicar | Olmesartan Medoxomil | 24 | suppressed |
| Constulose | Lactulose | 24 | suppressed |
| Lubiprostone | Lubiprostone | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 23 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Repatha Syringe | Evolocumab | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 18 |
| Fluocinonide | Fluocinonide | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 22 | suppressed |
| Clotrimazole | Clotrimazole | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Acarbose | Acarbose | 20 | suppressed |
| Armodafinil | Armodafinil | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lyrica | Pregabalin | 20 | suppressed |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Lisinopril | Lisinopril | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 18 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 18 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 18 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Alogliptin-Metformin | Alogliptin Benz/Metformin Hcl | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Modafinil | Modafinil | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Repaglinide | Repaglinide | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Ramelteon | Ramelteon | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Tavaborole | Tavaborole | 14 | suppressed |
| Ursodiol | Ursodiol | 14 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 13 | suppressed |
| Crestor | Rosuvastatin Calcium | 13 | suppressed |
| Dexilant | Dexlansoprazole | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 13 | suppressed |
| Flector | Diclofenac Epolamine | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Uloric | Febuxostat | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Rozerem | Ramelteon | 12 | suppressed |
| Savaysa | Edoxaban Tosylate | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Bystolic | Nebivolol Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Primidone | Primidone | 11 | suppressed |
| Procrit | Epoetin Alfa | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,204.90 · 142 records | E.R. Squibb & Sons, L.L.C. | ACCRUFER, ACTHAR, AIRSUPRA, AMVUTTRA, BREZTRI, BRILINTA, CAMZYOS, CAPVAXIVE, CREON, ELIQUIS, EVENITY, FARXIGA, FUROSCIX, Flector, JARDIANCE, Kerendia, LEQVIO, LINZESS, Licart, LifeVest, MOUNJARO, NEXLETOL, NURTEC ODT, NUZYRA, Ozempic, PANCREAZE, PROLIA, REPATHA, SAPIEN 3 Ultra RESILIA, TRELEGY ELLIPTA, Tirosint, Tymlos, VERQUVO, VYNDAQEL, Wegovy, ZAVZPRET, ZENPEP, ZEPBOUND | 26 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brilinta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error